Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?

  • P. Dostert
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)


This paper presents a rapid overview of the mechanism by which monoamine oxidase (MAO) catalyzes the deamination of its substrates, and highlights the stereoselective nature of the active site of the enzyme. With the help of a few selected examples it is also discussed which structural factors are thought to have a preponderant influence on the affinity and selectivity of molecules towards the active site of either form of MAO.


Monoamine Oxidase Transient Forebrain Ischemia Complex Partial Epilepsy Mitochondrial Monoamine Oxidase Cheese Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arai Y, Toyoshima Y, Kinemuchi H (1986) Studies of monoamine oxidase and semi-carbazide-sensitive amine oxidase. II. Inhibition by a-methylated substrate-analogue monoamines, α-methyltryptamine, β-methylbenzylamine and two enantiomers of β-methylbenzylamine. Jpn J Pharmacol 41: 191–197.PubMedCrossRefGoogle Scholar
  2. Berger PA, Barchas JD (1977) Monoamine oxidase inhibitors. Psychopharmacol Ser 2: 1173–1216.Google Scholar
  3. Burrows GD, Da Prada M (1989) Reversible MAO-A inhibitors as antidepressants. J Neural Transm [Suppl] 28.Google Scholar
  4. Cesura AM, Galva MD, Imhof R, Kyburz E, Picotti GB, Da Prada M (1989) [3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B. Eur J Pharmacol 162: 457–465.PubMedCrossRefGoogle Scholar
  5. Cesura AM, Bös M, Galva MD, Imhof R, Da Prada M (1990) Characterization of the binding of [3H]Ro 41-1049 to the active site of human monoamine oxidase-A. Mol Pharmacol 37: 358–366.PubMedGoogle Scholar
  6. Cesura AM, Kettler R, Imhof R, Da Prada M (1992) Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology 106: S15–S16.PubMedCrossRefGoogle Scholar
  7. Chrisp P, Mammen GJ, Sorkin EM (1991) Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson’s disease. Drugs Aging 1: 228–248.PubMedCrossRefGoogle Scholar
  8. Cohen G (1990) Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm [Suppl] 32: 229–238.Google Scholar
  9. Curet O, Damoiseau G, Aubin N (1992) Biochemical profile of befloxatone, a new reversible MAO-A inhibitor. Clin Neuropharmacol 15[Suppl 1]: 428B.Google Scholar
  10. Damsma G, Boisvert DP, Mudrick LA, Wenkstern D, Fibiger HC (1990) Effects of transient forebrain ischemia and pargyline on extracellular concentrations of dopamine, serotonin, and their metabolites in the rat striatum as determined by in vivo microdialysis. J Neurochem 54: 801–808.PubMedCrossRefGoogle Scholar
  11. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss P-C, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm [Suppl] 29: 279–292.Google Scholar
  12. Dosiert P (1984) Myth and reality of the classical MAO inhibitors. Reasons for seeking a new generation. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London, pp 9–24.Google Scholar
  13. Dostert P, Strolin Benedetti M (1986) Nouveaux inhibiteurs de la monoamine oxidase. Actal Chim Thér 13: 269–287.Google Scholar
  14. Dostert P, Strolin Benedetti M, Tipton KF (1989) Interactions of monoamine oxidase with substrates and inhibitors. Med Res Rev 9: 45–89.PubMedCrossRefGoogle Scholar
  15. Dostert P, Strolin Benedetti M (1991) Structure-modulated recognition of substrates and inhibitors by monoamine oxidases A and B. Biochem Soc Trans 19: 207–211.PubMedGoogle Scholar
  16. Dostert P, Strolin Benedetti M, Tipton KF (1991) New anticonvulsants with selective MAO-B inhibitory activity. Eur Neuropsychopharmacol 1: 317–319.CrossRefGoogle Scholar
  17. Dostert P, O’Brien EM, Tipton KF, Meroni M, Melloni P, Strolin Benedetti M (1992) Inhibition of monoamine oxidase by the R and S enantiomers of N[3-(2,4-dichloro-phenoxy)propyl]-N-methyl-3-butyn-2-amine. Eur J Med Chem 27: 45–52.CrossRefGoogle Scholar
  18. Egawa M, Inokuchi T, Ida S, Tobe A (1983) Effects of 4-(o-benzylphenoxy)-N-methyl-butylamine hydrochloride (MCI-2016) on monoamine metabolism in the brain. Nippon Yakurigaku Zasshi 82: 351–360.PubMedCrossRefGoogle Scholar
  19. Fowler CJ, Callingham BA, Mantle TJ, Tipton KF (1980) The effect of lipophilic compounds upon the activity of rat liver mitochondrial monoamine oxidase-A and — B. Biochem Pharmacol 29: 1177–1183.PubMedCrossRefGoogle Scholar
  20. Fowler CJ, Ross SB (1984) Selective inhibitors of monoamine oxidase A and B: biochemical, pharmacological, and clinical properties. Med Res Rev 4: 323–358.PubMedCrossRefGoogle Scholar
  21. Fuller RW (1968) Influence of substrate in the inhibition of rat liver and brain monoamine oxidase. Arch Int Pharmacodyn Ther 174: 32–36.PubMedGoogle Scholar
  22. Goldstein DS, Nadi NS, Stull R, Wyler AR, Porter RJ (1988) Levels of catechols in epileptogenic and nonepileptogenic regions of the human brain. J Neurochem 50: 225–229.PubMedCrossRefGoogle Scholar
  23. Ho BT (1972) Monoamine oxidase inhibitors. J Pharm Sci 61: 821–837.PubMedCrossRefGoogle Scholar
  24. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissues. Biochem Pharmacol 17: 1285–1297.PubMedCrossRefGoogle Scholar
  25. Knoll J, Magyar K (1972) Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 5: 393–408.PubMedGoogle Scholar
  26. Kumagae Y, Matsui Y, Iwata N (1990) Participation of type A monoamine oxidase in the activated deamination of brain monoamines shortly after reperfusion in rats. Jpn J Pharmacol 54: 407–413.PubMedCrossRefGoogle Scholar
  27. Kumlien E, Hilton-Brown P, Spännare B, Gillberg P-G (1992) In vitro quantitative autoradiography of [3H]-1-deprenyl and [3H]-PK 11195 binding sites in human epileptic hippocampus. Epilepsia 33: 610–617.PubMedCrossRefGoogle Scholar
  28. LeWitt PA, The Parkinson Study Group (1991) Deprenyl’s effect at slowing progression of parkinsonian disability: the DATATOP study. Acta Neurol Scand 84[Suppl 136]: 79–86.CrossRefGoogle Scholar
  29. Lorez HP, Harvey J, Wright L, Kollar S, Blaszat G, Thomas B, Martin JR, Kettler R, Da Prada M (1990) Moclobemide exhibits neuroprotective effects in hypoxic rat brain. In: Krieglstein J, Oberpichler H (eds) Pharmacology of cerebral ischemia. Wissenschaftliche Verlagsgesellschaft, Stuttgart, pp 477–484.Google Scholar
  30. Maker HS, Weiss C, Silides DJ, Cohen G (1981) Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 36: 589–593.PubMedCrossRefGoogle Scholar
  31. Matsui Y, Kumagae Y (1991) Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia. Neurosci Lett 126: 175–178.PubMedCrossRefGoogle Scholar
  32. Mazouz F, Lebreton L, Milcent R, Burstein C (1990) 5-Aryl-l,3,4-oxadiazol-2 (3H)-one derivatives and sulfur analogues as new selective and competitive monoamine oxidase type B inhibitors. Eur J Med Chem 25: 659–671.CrossRefGoogle Scholar
  33. Medvedev AE, Gorkin VZ (1992) Biogenic amines and monoamine oxidases in the regulation of activities of membrane-bound mitochondrial enzymes. Bio Amines 8: 323–337.Google Scholar
  34. O’Brien EM, Tipton KF, Strolin Benedetti M, Bonsignori A, Marrari P, Dostert P (1991) Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?. Biochem Pharmacol 41: 1731–1737.PubMedCrossRefGoogle Scholar
  35. O’Carroll A-M, Tipton KF, Sullivan JP, Fowler CJ, Ross SB (1987) Intra-and extras-ynaptosomal deamination of dopamine and noradrenaline by the two forms of human brain monoamine oxidase. Implications for the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in man. Bio Amines 4: 165–178.Google Scholar
  36. Palfreyman MG, Mcdonald IA, Bey P, Danzin C, Zreika M, Lyles GA, Fozard JR (1986) The rational design of suicide substrates of amine oxidases. Biochem Soc Trans 14: 410–413.PubMedGoogle Scholar
  37. Pintor M, Mefford IN, Hutter I, Pocotte SL, Wyler AR, Nadi NS (1990) Levels of biogenic amines, their metabolites, and tyrosine hydroxylase activity in the human epileptic temporal cortex. Synapse 5: 152–156.PubMedCrossRefGoogle Scholar
  38. Raigorodskaia DI, Medvedev AE, Gorkin VZ, Fedotova IB, Semiokhina AF (1991) Change in the catalytic properties of mitochondrial monoamine oxidase in experimental audiogenic epilepsy. Vopr Med Khim 37: 46–48.PubMedGoogle Scholar
  39. Seregi A, Serfözö P, Mergl Z, Schaefer A (1982) On the mechanism of the involvement of monoamine oxidase in catecholamin-estimulated prostaglandin biosynthesis in particulate fraction of rat brain homogenates: role of hydrogen peroxide. J Neurochem 38: 20–27.PubMedCrossRefGoogle Scholar
  40. Sinet PM, Heikkila RE, Cohen G (1980) Hydrogen peroxide production by rat brain in vivo. J Neurochem 34: 1421–1428.PubMedCrossRefGoogle Scholar
  41. Silverman RB (1984) Effect of β-methylation on inactivation of monoamine oxidase by N-cyclopropylbenzylamine. Biochemistry 23: 5206–5213.PubMedCrossRefGoogle Scholar
  42. Silverman RB (1991) The use of mechanism-based inactivators to probe the mechanism of monoamine oxidase. Biochem Soc Trans 19: 201–206.PubMedGoogle Scholar
  43. Silverman RB, Hoffman SF, Catus III WB (1980) A mechanism for mitochondrial monoamine oxidase catalyzed amine oxidation. J Am Chem Soc 102: 7126–7128.CrossRefGoogle Scholar
  44. Sobaniec W, Rudzinski P, Jankowicz E, Sobaniec-Lotowska M, Kulak W (1989) Cardiazol-induced seizures and the concentration of lipid peroxides in the brain of rats under the influence of valproic acid and vitamin E. Neuropatol Pol 27: 129–136.Google Scholar
  45. Strolin Benedetti M, Dostert P (1985) Stereochemical aspects of MAO interactions: reversible and selective inhibitors of monoamine oxidase. Trends Pharmacol Sci 6: 246–251.CrossRefGoogle Scholar
  46. Strolin Benedetti M, Dostert P (1989) Effect of selective monoamine oxidase substrates and inhibitors on lipid peroxidation and their possible involvement in affective disorders. In: Lerer B, Gershon S (eds) New directions in affective disorders. Springer, Berlin Heidelberg New York Tokyo, pp 156–160.CrossRefGoogle Scholar
  47. Strolin Benedetti M, Dostert P (1992) Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors. Adv Drug Res 23: 65–125.Google Scholar
  48. Tipton KF, O’Carroll A-M, Mantle TJ, Fowler CJ (1983) Factors involved in the selective inhibition of monoamine oxidase. Mod Probl Pharmacopsychiatry 19: 15–30.PubMedGoogle Scholar
  49. Tipton KF, Dostert P, Strolin Benedetti M (1984) Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. Academic Press, London.Google Scholar
  50. Weyler W, Hsu Y-P P, Breakefield XO (1990) Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47: 391–417.PubMedCrossRefGoogle Scholar
  51. White HL, Scates PW (1992) Mechanism of monoamine oxidase-A inhibition by BW 1370U87. Drug Dev Res 25: 191–199.CrossRefGoogle Scholar
  52. Willmore LJ, Triggs WJ (1984) Effect of phenytoin and corticosteroids on seizures and lipid peroxidation in experimental posttraumatic epilepsy. J Neurosurg 60: 467–472.PubMedCrossRefGoogle Scholar
  53. Youdim MBH, Da Prada M, Amrein R (1988) The cheese effect and new reversible MAO-A inhibitors. J Neural Transm [Suppl] 26.Google Scholar
  54. Yu PH, Bailey BA, Durden DA, Boulton AA (1986) Stereospecific deuterium substitution at the a-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues. Biochem Pharmacol 35: 1027–1036.PubMedCrossRefGoogle Scholar
  55. Yu PH, Davis BA (1988) Stereospecific deamination of benzylamine catalyzed by different amine oxidases. Int J Biochem 20: 1197–1201.PubMedCrossRefGoogle Scholar
  56. Zeller EA (1971) Amine oxidases. In: Brodie BB, Gillette JR, Ackerman HS (eds) Handbook of experimental pharmacology, vol 28. Springer, Berlin Heidelberg New York, pp 518–535.Google Scholar
  57. Zhang J, Piantadosi CA (1991) Prevention of H2O2 generation by monoamine oxidase protects against CNS O2 toxicity. J Appl Physiol 71: 1057–1061.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • P. Dostert
    • 1
  1. 1.Famitalia Carlo Erba-Research and DevelopmentMilanItaly

Personalised recommendations